This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results
There were no statistically significant differences in costs between any of the interventions. There were no significant differences in the QALYs gained between conservative therapy and no treatment; and between duloxetine and duloxetine plus conservative therapy. With duloxetine, the QALYs gained were 0.027 compared with no treatment, and 0.031 compared with conservative therapy. With duloxetine plus conservative therapy, they were 0.025 compared with no treatment, and 0.030 compared with conservative therapy.
The incremental cost per QALY gained varied depending on the propensity score matching method, as did the probability that this ratio was below the cost-effectiveness threshold of £20,000.
There was a low probability that conservative therapy was cost-effective compared with no treatment, ranging from 0.28 to 0.35, with ICERs from £2,970 to £6,379. There was a high probability that duloxetine treatment was cost-effective compared with no treatment, ranging from 0.86 to 1.00 and that it was cost-effective compared with conservative therapy, ranging from 0.91 to 1.00. The probability that duloxetine treatment was cost-effective compared with duloxetine plus conservative therapy ranged from 0.54 to 0.59. The probability that duloxetine treatment plus conservative therapy was cost-effective compared with no treatment ranged from 0.74 to 0.92, and compared with conservative therapy it ranged from 0.68 to 0.99.
Analysis and results:
The costs and benefits were synthesised, using an incremental cost-utility ratio, but only the incremental QALYs were reported and no absolute values. Adequate statistical analyses were undertaken, and the potential impact of missing data on the results was tested using multiple imputation methods. Both the methods and the results were reported sufficiently. The main limitation was that effectiveness data were from a cohort study rather than a randomised controlled trial, but appropriate statistical techniques were used to control for any selection bias.
Concluding remarks:
: The methods were good, and they and the results were reported sufficiently. Given the limitations of the design of the source study, as acknowledged by the authors, their conclusions appear to be appropriate.
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